Arwa Younis1, Ilan Goldenberg2, Shamroz Farooq2, Hagai Yavin3, James Daubert4, Merritt Raitt5, Alexander Mazur6, David T Huang2, Brent L Mitchell7, Mayer R Rashtian8, Stephen Winters9, Margot Vloka10, Mehmet Aktas2, Matthew A Bernabei11, Christopher A Beck12, Scott McNitt2, Wojciech Zareba13. 1. Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA; Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: or.younis@gmail.com. 2. Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. 3. Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. 4. Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. 5. Division of Cardiology, VA Portland Health Care System and Knight Cardiovascular Institute, Oregon Health and Sciences University, Portland VA Medical Center, Portland, Oregon, USA. 6. Division of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa, USA. 7. Division of Cardiology, University of Calgary, Calgary, Canada. 8. Department of Cardiology, Huntington Memorial Hospital, Pasadena, California, USA. 9. Department of Cardiovascular Medicine, Morristown Medical Center, Morristown, New Jersey, USA. 10. Cardiology Division, Saint Alphonsus Health System, Boise, Idaho, USA. 11. Lancaster Heart and Vascular Institute, Lancaster, Pennsylvania, USA. 12. Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA. 13. Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: wojciech_zareba@urmc.rochester.edu.
Abstract
BACKGROUND: The RAID (Ranolazine Implantable Cardioverter-Defibrillator) randomized placebo-controlled trial showed that ranolazine treatment was associated with reduction in recurrent ventricular tachycardia (VT) requiring appropriate implantable cardioverter-defibrillator (ICD) therapy. OBJECTIVES: This study aimed to identify groups of patients in whom ranolazine treatment would result in the highest reduction of ventricular tachyarrhythmia (VTA) burden. METHODS: Andersen-Gill analyses were performed to identify variables associated with risk for VTA burden among 1,012 patients enrolled in RAID. The primary endpoint was VTA burden defined as VTA episodes requiring appropriate treatment. RESULTS: Multivariate analysis identified 7 factors associated with increased VTA burden: history of VTA, age ≥65 years, New York Heart Association functional class ≥III, QRS complex (≥130 ms), low ejection fraction (<30%), atrial fibrillation (AF), and concomitant antiarrhythmic drug (AAD) therapy. The effect of ranolazine on VTA burden was seen among patients without concomitant AAD therapy (HR [HR]: 0.68; 95% CI: 0.55-0.84; P < 0.001), whereas no effect was seen among those who are concomitantly treated with other AADs (HR: 1.33; 95% CI: 0.90-1.96; P = 0.16); P = 0.003 for interaction. In patients with cardiac resynchronization therapy (CRT) ICDs, ranolazine treatment was associated with a 36% risk reduction for VTA recurrence (HR: 0.64; 95% CI: 0.47-0.86; P < 0.001), whereas among patients with ICDs without CRT no significant effect was noted (HR: 0.94; 95% CI: 0.74-1.18; P = 0.57); P = 0.047 for interaction. CONCLUSIONS: In patients with high risk for VTA, ranolazine is effective in reducing VTA burden, with significantly greater effect in CRT-treated patients, those without AF, and those not treated with concomitant AADs. In patients already on AADs or those with AF, the addition of ranolazine did not affect VTA burden. (Ranolazine Implantable Cardioverter-Defibrillator Trial [RAID]; NCT01215253).
BACKGROUND: The RAID (Ranolazine Implantable Cardioverter-Defibrillator) randomized placebo-controlled trial showed that ranolazine treatment was associated with reduction in recurrent ventricular tachycardia (VT) requiring appropriate implantable cardioverter-defibrillator (ICD) therapy. OBJECTIVES: This study aimed to identify groups of patients in whom ranolazine treatment would result in the highest reduction of ventricular tachyarrhythmia (VTA) burden. METHODS: Andersen-Gill analyses were performed to identify variables associated with risk for VTA burden among 1,012 patients enrolled in RAID. The primary endpoint was VTA burden defined as VTA episodes requiring appropriate treatment. RESULTS: Multivariate analysis identified 7 factors associated with increased VTA burden: history of VTA, age ≥65 years, New York Heart Association functional class ≥III, QRS complex (≥130 ms), low ejection fraction (<30%), atrial fibrillation (AF), and concomitant antiarrhythmic drug (AAD) therapy. The effect of ranolazine on VTA burden was seen among patients without concomitant AAD therapy (HR [HR]: 0.68; 95% CI: 0.55-0.84; P < 0.001), whereas no effect was seen among those who are concomitantly treated with other AADs (HR: 1.33; 95% CI: 0.90-1.96; P = 0.16); P = 0.003 for interaction. In patients with cardiac resynchronization therapy (CRT) ICDs, ranolazine treatment was associated with a 36% risk reduction for VTA recurrence (HR: 0.64; 95% CI: 0.47-0.86; P < 0.001), whereas among patients with ICDs without CRT no significant effect was noted (HR: 0.94; 95% CI: 0.74-1.18; P = 0.57); P = 0.047 for interaction. CONCLUSIONS: In patients with high risk for VTA, ranolazine is effective in reducing VTA burden, with significantly greater effect in CRT-treated patients, those without AF, and those not treated with concomitant AADs. In patients already on AADs or those with AF, the addition of ranolazine did not affect VTA burden. (Ranolazine Implantable Cardioverter-Defibrillator Trial [RAID]; NCT01215253).
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: J Am Coll Cardiol Date: 2017-04-28 Impact factor: 24.094
Authors: Roderick Tung; Marmar Vaseghi; David S Frankel; Pasquale Vergara; Luigi Di Biase; Koichi Nagashima; Ricky Yu; Sitaram Vangala; Chi-Hong Tseng; Eue-Keun Choi; Shaan Khurshid; Mehul Patel; Nilesh Mathuria; Shiro Nakahara; Wendy S Tzou; William H Sauer; Kairav Vakil; Usha Tedrow; J David Burkhardt; Venkatakrishna N Tholakanahalli; Anastasios Saliaris; Timm Dickfeld; J Peter Weiss; T Jared Bunch; Madhu Reddy; Arun Kanmanthareddy; David J Callans; Dhanunjaya Lakkireddy; Andrea Natale; Francis Marchlinski; William G Stevenson; Paolo Della Bella; Kalyanam Shivkumar Journal: Heart Rhythm Date: 2015-05-30 Impact factor: 6.343
Authors: Eleanor B Schron; Derek V Exner; Qing Yao; Louise S Jenkins; Jonathan S Steinberg; James R Cook; Steven P Kutalek; Peter L Friedman; Rosemary S Bubien; Richard L Page; Judy Powell Journal: Circulation Date: 2002-02-05 Impact factor: 29.690
Authors: Ilan Goldenberg; Valentina Kutyifa; Helmut U Klein; David S Cannom; Mary W Brown; Ariela Dan; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Josef Kautzner; Robert Klempfner; Malte Kuniss; Bela Merkely; Marc A Pfeffer; Aurelio Quesada; Sami Viskin; Scott McNitt; Bronislava Polonsky; Ali Ghanem; Scott D Solomon; David Wilber; Wojciech Zareba; Arthur J Moss Journal: N Engl J Med Date: 2014-03-30 Impact factor: 91.245
Authors: Ana Claudia C de Ornelas Maia; Gastão Soares-Filho; Valeska Pereira; Antonio Egidio Nardi; Adriana Cardoso Silva Journal: Prim Care Companion CNS Disord Date: 2013-04-18